In this study, we developed a diagnostic tool for sEV analyses to be used on liquid biopsies from NSCLC patients, an immuno-PCR based on affibody–DNA conjugates towards tumor-associated membrane receptors EGFR, HER2, and IGF-1R, all relevant as precision medicine targets in NSCLC and to some extent in other tumor types, e.g., breast cancer and/or as bypass drivers in TKI resistance development [11,14,17,18]. This evidence concerns the gene EGFR and breast carcinoma.